Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Survey Among Early-Adopting Physicians
Purpose
Triamcinolone acetonide injectable suspension (SCS-TA; Xipere®) for suprachoroidal use was recently approved in the US for the treatment of uveitic macular edema (UME). Here, experience with the injection procedure among early adopters of SCS-TA along with patient outcomes were evaluated
Methods
Twelve retina/uveitis specialists were surveyed with a series of pre-defined questions probing their experience with SCS-TA
Results
Across respondents, at least 291 SCS-TA injections were administered to 243 patients with various uveitis etiologies, chronicity, and anatomical subtypes. Reasons for SCS-TA adoption included the potential lower risk for intraocular pressure elevations (n=12;100%) and longer duration of action (n=11;92%) versus intravitreal steroids/implants. Nearly all specialists (n=11;92%) found the injection somewhat/very easy post-training, with most (n=9;75%) procedurally comfortable after 2-5 injections. Patients typically gained 2-3 lines of vision by first follow-up visit, ~4-6 weeks post-injection, and most specialists (n=11;92%) reported 100 to ≥150 μm reductions in central subfield thickness. There were no unexpected/new safety findings. Most (n=11;92%) respondents were satisfied with SCS-TA treatment.
Conclusion
Perceptions and experiences of early adopters with treatments involving new delivery techniques can reveal educational gaps and provide real world evidence. Physicians found SCS-TA injection easy to learn with patient improvements in vision and in macular edema aligned with clinical trial data.
Conflict of interest
Yes
Details of conflicting interests
Consultant for Bausch and Lomb
Authors 1
Last name
EMAMI
Initials of first name(s)
P
Department
Ophthalmology
City
Sacramento, CA
Country
United States
Authors 2
Last name
Xipere Early adopters Survey Participants
Initials of first name(s)
-
Department
Ophthalmology
City
-
Country
United States
This website uses cookies to ensure you get the best experience on our website.
Learn more